As an unapproved drug, leronlimab is not available to the general public. However, certain patients who are facing serious illnesses, and who have exhausted all available treatment options, may be able to receive early access to investigational drugs that haven’t yet been approved by government regulatory agencies.
It is important that you first consult with your healthcare provider before inquiring about potential access to leronlimab. Your healthcare provider can then use the contact information below to submit access request(s) to the Company.
All inquiries relating to potentially obtaining access to leronlimab need to be made in writing, and submitted to: dai@cytodyn.com
For the most up-to-date information regarding The Right to Try Act, and/or potential access for patients who have been diagnosed with life-threatening diseases or conditions, have tried all approved treatment options, and are unable to participate in a clinical trial to access certain investigational treatment options, please visit FDA.gov and review its overview regarding “Right to Try” allowances. https://www.fda.gov/patients/learn-about-expa.../right-try
WARNING: Leronlimab has not received regulatory approval from the FDA. The potential risks and benefits are not known. Doctors and patients should consider all possible benefits and risks before applying for expanded access (or right to try) to leronlimab.
https://www.cytodyn.com/investors/investor-faqs
It is important that you first consult with your healthcare provider before inquiring about potential access to leronlimab. Your healthcare provider can then use the contact information below to submit access request(s) to the Company.
All inquiries relating to potentially obtaining access to leronlimab need to be made in writing, and submitted to: dai@cytodyn.com
For the most up-to-date information regarding The Right to Try Act, and/or potential access for patients who have been diagnosed with life-threatening diseases or conditions, have tried all approved treatment options, and are unable to participate in a clinical trial to access certain investigational treatment options, please visit FDA.gov and review its overview regarding “Right to Try” allowances. https://www.fda.gov/patients/learn-about-expa.../right-try
WARNING: Leronlimab has not received regulatory approval from the FDA. The potential risks and benefits are not known. Doctors and patients should consider all possible benefits and risks before applying for expanded access (or right to try) to leronlimab.
https://www.cytodyn.com/investors/investor-faqs
1
